ARA-290 (Cibinetide) Peptide research-grade
ARA-290 (Cibinetide) Peptide

ARA-290 (Cibinetide) Peptide

$43.00

Laboratory-grade ARA-290 (Cibinetide) Peptide is a non-hematopoietic EPO receptor agonist peptide used in tissue-protection research. Research buyers select this listing for pre-clinical work on innate repair receptor signaling models—not for clinical, veterinary, or consumer use.

For Research Use Only. Not for human use.

For Research Use Only — Not for Human Consumption
Free shipping on all orders over $200 (US)

  • 99% Purity – Third-Party Tested
  • Fast & Reliable Shipping
Guaranteed Checkout

Accepted Payment Methods

For Research Use Only. Not for human use.

ARA-290 (Cibinetide) Peptide research-grade

Overview

ARA-290 (Cibinetide) Peptide is supplied as a research-grade catalog material for controlled laboratory investigation.

Laboratories choose this item when protocols need clear identification, consistent labeling, and documentation suitable for reproducible experimental workflows.

Catalog packaging and research-use labeling help purchasing and bench teams keep procurement records aligned with the physical vial.

Research Context for ARA-290 (Cibinetide) Peptide

Work involving ARA-290 (Cibinetide) Peptide typically focuses on in vitro systems, assay development, and mechanistic model studies.

Teams confirm lot details before setup so conditions stay traceable across repeats and collaborative sites.

Published literature can inform starting ranges for related experimental designs. Each laboratory should still validate performance with its own instruments, plates, and detection chemistry.

Pilot runs are useful before committing larger plate sets, especially when detection chemistry or incubation windows are being optimized.

Documented Attributes

Key catalog attributes for this material include:

  • Research-grade material intended for laboratory investigation only
  • Catalog labeling aligned with research procurement channels
  • Suitable for method development and comparative assay workflows
  • Documentation packages available where provided for the listed lot

Laboratory Handling Notes

Receiving and Identity Checks

Before opening a vial of ARA-290 (Cibinetide) Peptide, confirm the physical label against the purchase order and packing list.

Retain outer packaging until identity checks are complete, and report damaged seals to purchasing before experimental work continues.

Reconstitution and Aliquoting

Handle this material according to institutional SOPs for weighing, reconstitution, aliquoting, and storage.

Record lot identifiers in laboratory notebooks before reconstitution. Verify solvent compatibility and storage temperature against your validated process.

Prepare assay buffers and consumables before opening the vial to reduce hold time. Keep unused aliquots labeled with date, solvent, and concentration for later repeats.

Chain of Custody

Keep chain-of-custody notes with inventory checks when material moves between freezers or benches.

Use dedicated spatulas and clean balances to avoid cross-contamination between catalog items. Schedule thaw cycles intentionally rather than repeated freeze-thaw of the same aliquot.

Secondary containment trays reduce spill risk during multi-step reconstitution. Cold-chain interruptions should be noted even when the vial remains sealed.

Why Laboratories Source ARA-290 (Cibinetide) Peptide

Procurement and research teams often select this catalog item because it supports:

  • Clear research-use labeling for compliance-aligned purchasing
  • Consistent product identification across multi-lot studies
  • Fit for reference, screening, and mechanistic laboratory models
  • Straightforward catalog support for planning and documentation

Study Planning and Quality Documentation

Before starting experimental work with ARA-290 (Cibinetide) Peptide, review any COA or quality files provided with the shipment.

Align your protocol with institutional research requirements and keep use within the labeled research context.

File catalog documentation with the study records at receipt. These steps help keep experiments comparable over time when using ARA-290 (Cibinetide) Peptide in sequential study phases.

Method Development Tips

Method development often begins with small pilot plates before larger screening panels.

Document buffer lots, incubation times, and detection settings alongside the material lot number.

If results diverge from historical baselines, re-check reconstitution volume and storage history first. Shared equipment logs help explain variance when multiple operators run the same protocol.

Inventory and Training

Update digital inventory immediately after opening a new lot of ARA-290 (Cibinetide) Peptide.

Training new staff on labeling conventions reduces mix-ups across similar catalog SKUs. When transferring methods between sites, share both the written SOP and the lot metadata package.

Dispose of residual solutions according to institutional chemical hygiene rules. Do not repurpose research materials for any non-laboratory application.

Periodic inventory reconciliation keeps expired or depleted lots from entering active workflows. For related catalog options, browse adjacent research categories on this site after confirming your assay needs.

For Research Use Only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease.

Peptide Research

For Research Use Only. Not for human use.

PubMed (NIH/NLM) records related to this compound for laboratory literature review. Inclusion does not imply suitability for any use beyond controlled research. Each note below is a research-framed summary using compliance-safe wording.

Showing 17 PubMed records. Displaying 10 per page.

  1. van Velzen M et al. (2014). ARA 290 for investigation of small fiber neuropathy in sarcoidosis [PMID: 24555851]

    Laboratory literature summary: ARA 290 for investigation of small fiber neuropathy in sarcoidosis. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  2. Dahan A et al. (2013). Laboratory research record on ARA-290 (Cibinetide) [PMID: 24136731]

    PubMed laboratory record discussing ARA-290 (Cibinetide) in a research context. Review the full methods and limitations on PubMed; research use only.

  3. Zhang W et al. (2016). ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration… [PMID: 26774587]

    Laboratory literature summary: ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  4. Al-Onaizi MA et al. (2022). Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates… [PMID: 34343617]

    Laboratory literature summary: Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  5. Brines M et al. (2015). Laboratory research record on ARA-290 (Cibinetide) [PMID: 25387363]

    PubMed laboratory record discussing ARA-290 (Cibinetide) in a research context. Review the full methods and limitations on PubMed; research use only.

  6. Watanabe M et al. (2016). A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation… [PMID: 26683514]

    Laboratory literature summary: A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  7. Mohtavinejad N et al. (2021). Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for… [PMID: 35317117]

    Laboratory literature summary: Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  8. Swartjes M et al. (2014). ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces… [PMID: 24529189]

    Laboratory literature summary: ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  9. Heij L et al. (2012). Laboratory research record on ARA-290 (Cibinetide) [PMID: 23168581]

    PubMed laboratory record discussing ARA-290 (Cibinetide) in a research context. Review the full methods and limitations on PubMed; research use only.

  10. Nairz M et al. (2017). Cibinetide dampens innate immune cell functions thus ameliorating the course of… [PMID: 29026145]

    Laboratory literature summary: Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  11. Yao M et al. (2021). Cibinetide Protects Isolated research subjects Islets in a Stressful Environment and… [PMID: 34498509]

    Laboratory literature summary: Cibinetide Protects Isolated research subjects Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  12. Yao M et al. (2020). Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand [PMID: 32345869]

    Laboratory literature summary: Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  13. Lois N et al. (2020). Laboratory research record on ARA-290 (Cibinetide) [PMID: 32674280]

    PubMed laboratory record discussing ARA-290 (Cibinetide) in a research context. Review the full methods and limitations on PubMed; research use only.

  14. Awida Z et al. (2021). The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro… [PMID: 35008482]

    Laboratory literature summary: The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  15. Culver DA et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in research subjects With… [PMID: 28475703]

    Laboratory literature summary: Cibinetide Improves Corneal Nerve Fiber Abundance in research subjects With Sarcoidosis-Associated Small Nerve Fiber Loss and…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  16. Bitto A et al. (2018). Laboratory research record on ARA-290 (Cibinetide) [PMID: 29223734]

    PubMed laboratory record discussing ARA-290 (Cibinetide) in a research context. Review the full methods and limitations on PubMed; research use only.

  17. O'Leary OE et al. (2019). The vasoreparative potential of endothelial colony-forming cells in the ischemic… [PMID: 30876881]

    Laboratory literature summary: The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

Browse the full PubMed index: PubMed search.

Additional information

Weight .125 lbs
Dimensions 9 × 7 × .5 in
Size: No selection

5 mg, 10 mg, 16 mg

Keep lyophilized peptides sealed in their original vial, protected from light and humidity, and store at -4°F or colder for optimal long-term stability in research settings; short-term refrigeration at around 39°F suffices for immediate use within weeks, though freezer storage maximizes integrity across extended research timelines.

Frequently Asked Questions

What is ARA-290 (Cibinetide) Peptide?

ARA-290 (Cibinetide) Peptide is supplied as a research-grade catalog material for controlled laboratory investigation only.

What is ARA-290 (Cibinetide) Peptide used for?

This product is intended for research purposes only and is not approved for human or clinical use.

What form does ARA-290 (Cibinetide) Peptide come in?

Most catalog items in this range are supplied as lyophilized (freeze-dried) powder unless otherwise stated on the product page.

How should ARA-290 (Cibinetide) Peptide be stored?

Store according to the product label and your institutional SOPs, typically in a cool, dry place. Refrigeration or freezer storage may be required depending on the material.

Is this product safe for human use?

No. This product is strictly labeled for research use only and is not for human use.

Do I need a prescription to purchase this product?

Because it is sold as a research chemical, a prescription is not required. Use is restricted to laboratory research.

How is the product shipped?

Shipping methods and transit times vary. Products are packed for secure transit. For more info, visit: https://www.nationwidepeptides.com/shipping-and-payments/

Is there a return or refund policy?

Policies cover damaged or faulty shipments; returns are limited due to the nature of research materials. For more info, visit: https://www.nationwidepeptides.com/return-policy/

How do I verify product quality?

Quality documentation may include third-party testing or certificates of analysis (COA) where provided. For more info, visit: https://www.nationwidepeptides.com/coa/